Abstract
Cells constantly adapt to external humoral cues like cytokines and hormones, but practically most cellular behavior is under locally guided control via cell–cell interactions. Galectins (Gals) are one of the most prominent members of the group of molecules involved in this intercellular signaling. They are the family of β-galactoside specific lectins and consist of 15 different types, each with a specific function. They play crucial role in the immune system, inflammation, wound healing and carcinogenesis. In recent times, the role of Gals in the development of cardiovascular disease (CVD) has gained attention. Gals have been reported to act ambiguously by both relieving ischemia and accelerating atherosclerosis. Atherosclerosis can ultimately lead to myocardial infarction or ischemic stroke, which are both associated with Gals. There is also a role for Gals in the development of myocarditis by their influence on inflammatory processes. Moreover, Gal acts as a biomarker for the severity of myocardial ischemia and heart failure (HF). This review summarizes the association between Gals and the development and pathogenesis of CVD like atherosclerosis, stroke, myocardial infarction, and HF. A comprehensive outline of the association between Gals and more general mechanisms such as angiogenesis, arteriogenesis and atherosclerosis has also been provided. Modulation of Gal signaling holds great promise for the treatment of CVD as evident from preclinical studies.
Keywords: Angiogenesis, atherosclerosis, cardiovascular disease, galectin, therapy.
Current Vascular Pharmacology
Title:Galectins-A Potential Target for Cardiovascular Therapy
Volume: 15 Issue: 4
Author(s): Ghulam Md. Ashraf*, Asma Perveen, Syed Kashif Zaidi, Ausaf Ahmad, Shazi Shakil, Chelapram Kandy Firoz, Nasimudeen R. Jabir, Iftekhar Hassan, Taqi Ahmad Khan, Nagendra Sastry Yarla and Shams Tabrez*
Affiliation:
- King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589,Saudi Arabia
- King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589,Saudi Arabia
Keywords: Angiogenesis, atherosclerosis, cardiovascular disease, galectin, therapy.
Abstract: Cells constantly adapt to external humoral cues like cytokines and hormones, but practically most cellular behavior is under locally guided control via cell–cell interactions. Galectins (Gals) are one of the most prominent members of the group of molecules involved in this intercellular signaling. They are the family of β-galactoside specific lectins and consist of 15 different types, each with a specific function. They play crucial role in the immune system, inflammation, wound healing and carcinogenesis. In recent times, the role of Gals in the development of cardiovascular disease (CVD) has gained attention. Gals have been reported to act ambiguously by both relieving ischemia and accelerating atherosclerosis. Atherosclerosis can ultimately lead to myocardial infarction or ischemic stroke, which are both associated with Gals. There is also a role for Gals in the development of myocarditis by their influence on inflammatory processes. Moreover, Gal acts as a biomarker for the severity of myocardial ischemia and heart failure (HF). This review summarizes the association between Gals and the development and pathogenesis of CVD like atherosclerosis, stroke, myocardial infarction, and HF. A comprehensive outline of the association between Gals and more general mechanisms such as angiogenesis, arteriogenesis and atherosclerosis has also been provided. Modulation of Gal signaling holds great promise for the treatment of CVD as evident from preclinical studies.
Export Options
About this article
Cite this article as:
Md. Ashraf Ghulam *, Perveen Asma , Zaidi Kashif Syed , Ahmad Ausaf , Shakil Shazi , Firoz Kandy Chelapram , Jabir R. Nasimudeen , Hassan Iftekhar , Khan Ahmad Taqi , Yarla Sastry Nagendra and Tabrez Shams *, Galectins-A Potential Target for Cardiovascular Therapy, Current Vascular Pharmacology 2017; 15 (4) . https://dx.doi.org/10.2174/1570161115666170201113046
DOI https://dx.doi.org/10.2174/1570161115666170201113046 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clonetics
Current Drug Metabolism EMCA and DEEM as Michael Reagents Used in Organic Synthesis
Current Organic Chemistry G Protein-Activated Inwardly Rectifying Potassium Channels as Potential Therapeutic Targets
Current Pharmaceutical Design Fetal Origins of Cardiovascular Disease
Current Cardiology Reviews Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?
Current Drug Therapy Dendrimer-drug Conjugates in Drug Delivery and Targeting
Pharmaceutical Nanotechnology Novel Direct Anticoagulants and Atherosclerosis
Current Vascular Pharmacology NADPH Oxidases in the Heart
Current Cardiology Reviews Cerebral White Matter Lesions, Risk of Stroke and Cerebrovascular Protection with Angiotensin Receptor Blockers
Current Drug Therapy 5-HT7 Receptor Ligands: Recent Developments and Potential Therapeutic Applications
Mini-Reviews in Medicinal Chemistry Coffee and Caffeine Effects on Hypertension
Current Hypertension Reviews S-Nitrosylation: Targets, Controls and Outcomes
Current Genomics PET Imaging of Adenosine Receptors in Diseases
Current Topics in Medicinal Chemistry Editorial
Drug Metabolism Letters The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design Development of COX-2 Selective Inhibitors - Therapeutic Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Aneurysm of the Communicating Vein Between the Left Renal Vein and Left Ascending Lumbar Vein Mimicking Retroperitoneal Lymphadenopathy: A Case Report
Current Medical Imaging Hemodynamic Changes after Continuing or Omitting Regular Angiotensin Converting Enzyme Inhibitors before Cataract Surgery: A Comparative Study
Current Hypertension Reviews Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems
Current Neuropharmacology Abstracts from Speakers
Cardiovascular & Hematological Disorders-Drug Targets